A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
Hypertension

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Blood Pressure, Hypertension, Resistant Hypertension
Eligibility Criteria
Inclusion criteria:
- Diagnosis of hypertension with mean sitting systolic blood pressure (MSSBP) ≥140 millimeters of mercury (mmHg) and <180 mmHg
- Stable on a three-drug regimen (including a diuretic) for at least 4 weeks for the treatment of resistant hypertension
- Male and female participants 18 to 75 years of age
Exclusion criteria:
- Recent history of myocardial infarction (MI), heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack
- Clinically significant electrocardiography (ECG) findings related to cardiac conduction defects
- Type 1 diabetes or uncontrolled type 2 diabetes (haemoglobin A1c [HbA1c] >9%)
- Malignancies within the last 5 years (excluding basal cell skin cancer)
Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Horizon Research Group, Inc
- Cochise Clinical Research
- Clinical Solutions Advantage
- Michael Waldman, MD
- Long Beach Center for Clinical Research
- Clinical Trials Research
- Orange County Research Center
- Metro Clinical Research
- Meridien Research
- Clinical Research of So. Florida
- Jacksonville Heart Center
- FPA Clinical Research
- Accelovance
- Cardio-Pulminary Associates
- Meridien Research
- Northwest Clinical Trials
- Provident Clinical Research
- Cedar-Crosse Research Centereet
- Provident Clinical Research
- Accelovance
- Peter A. Holt
- MD Medical Research
- Chelsea Internal Medicine
- New York Cardiovascular Associates
- Charlotte Clinical Research
- Northstate Clinical Research
- Community Research
- Tipton Medical & Diagnostic Center
- Medical Research South
- Mountain View Clinical Research Associates
- Clinical Research Associates, Inc
- Punzi Medical Center
- KRK Medical Research
- DCOL Center for Clinical Research
- Daniel Gottlieb, MD
- Rainier Clinical Research Center
- Gemini Scientific
- Encode Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
LCI699 0.25 mg BID
LCI699 1 mg QD
LCI699 0.5 mg followed by LCI699 1 mg BID
Eplerenone 50 mg BID
Placebo
Following a 2-week placebo run-in period, participants received LCI699 0.25 mg, capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
Following a 2-week placebo run-in period, participants received LCI699 1 mg, capsules, orally, once daily (QD), with or without food for up to 8 weeks.
Following a 2-week placebo run-in period, participants received LCI699 0.5 mg, capsules, orally, BID, with or without food for up to 4 weeks, followed by LCI699 1 mg, capsules, orally, BID with or without food for up to 4 weeks.
Following a 2-week placebo run-in period, participants received eplerenone 50 mg, capsules, orally, BID, with or without food for up to 8 weeks.
For a 2-week placebo run-in period, followed by 8 weeks of the treatment period, participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food.